FMC Corporation — Apr 29, 2026 release

FMC expects Adjusted EPS to be in the range of $0.16 to $0.26 in the second quarter, which represents a 70 percent decrease at the midpoint versus second quarter 2025 due to lower Adjusted EBITDA as well as higher interest expense to a lesser degree. The midpoint of first-half guidance implies a second-half sales increase of 1 percent versus prior year. Price is expected to be a mid-single digit headwind, driven by competitive market conditions for core portfolio products and pricing actions to support branded Rynaxypyr® active strategy. Lower price and a minor FX headwind are expected to be more than offset by volume growth, driven primarily by increased sales of products with new active ingredients. Second-half Adjusted EBITDA is expected to decrease 6 percent as lower price and a minor FX headwind are partially offset by higher volume and favorable costs. Second-half Adjusted EPS is expected to decline 15 percent compared to second half 2025 due to lower Adjusted EBITDA, higher tax, and higher interest expense. Page 5 / FMC Corporation reports first quarter 2026 results above guidance with Adjusted EBITDA above high end of range, reaffirms full-year outlook Full-Year 2026 Outlook 1 Q2 2025 Outlook 1 First-Half Outlook 1 Second-Half Outlook 1 Revenue Excl. India $3.60 billion to $3.80 billion $850 million to $900 million $1.61 billion to $1.66 billion $1.99 billion to $2.14 billion Growth at midpoint vs. 2025* (5)% (17)% (11)% 1% Adjusted EBITDA $670 million to $730 million $130 million to $150 million $202 m